Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice

被引:4
|
作者
Wirrell, Elaine C. [1 ]
Lagae, Lieven [2 ]
Scheffer, Ingrid E. [3 ,4 ]
Cross, J. Helen [5 ,6 ]
Specchio, Nicola [7 ]
Strzelczyk, Adam [8 ,9 ]
机构
[1] Mayo Clin, Dept Neurol, Div Child & Adolescent Neurol & Epilepsy, 200 1st St SW, Rochester, MN 55905 USA
[2] Univ Leuven, Dept Pediat Neurol, European Reference Network EpiCARE, Leuven, Belgium
[3] Univ Melbourne, Austin Hosp, Florey & Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[4] Univ Melbourne, Royal Childrens Hosp, Florey & Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[5] UCL NIHR BRC Great Ormond St Inst Child Hlth, Dev Neurosci Res & Teaching Dept, London, England
[6] Great Ormond St Hosp Sick Children, Dept Neurol, London, England
[7] SIPSIC, Rome, Italy
[8] Univ Hosp Frankfurt, Goethe Univ Frankfurt, Epilepsy Ctr Frankfurt Rhine Main, Frankfurt, Germany
[9] Univ Hosp Frankfurt, Dept Neurol, Frankfurt, Germany
关键词
antiseizure medications; Dravet syndrome; fenfluramine; Lennox-Gastaut syndrome; polytherapy; SEVERE MYOCLONIC EPILEPSY; ANTI-SEIZURE MEDICATIONS; DRUG-INTERACTIONS; TERM EFFICACY; RISK-FACTORS; INFANCY; METAANALYSIS; POPULATION; DIAGNOSIS;
D O I
10.1002/epi4.12998
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fenfluramine (FFA), an antiseizure medication (ASM) with serotonergic and sigma-1 receptor activity, is used to manage patients with developmental and epileptic encephalopathies (DEEs). It is approved in the US for treating seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients >= 2 years old and as add-on therapy for seizures associated with DS and LGS in the EU, UK, and Japan in similarly aged patients. Consensus guidelines for treatment of DS have recommended FFA to be an early-line ASM, and it has also shown efficacy in managing seizures associated with LGS. DS and LGS are DEEs associated with a range of seizure types, developmental impairments, and multiple comorbidities. Here we provide case vignettes describing 4 patients (3 DS and 1 LGS) aged 4-29 years old in whom up to 14 ASMs had previously failed, to illustrate real-world practice issues encountered by neurologists. This review provides guidance on the use of FFA in the context of ASM polytherapy and drug-drug interactions (DDIs), behavioral issues, dose titration, and adverse events. Along with data from the clinical trial program, these case vignettes emphasize the low risk of DDIs, a generally well-tolerated safety profile, and other seizure and nonseizure benefits (eg, improved cognition and sleep) associated with the use of FFA in DS or LGS.Plain Language SummaryFenfluramine is used to treat seizures in individuals with Dravet syndrome and Lennox-Gastaut syndrome, but there are a range of issues that clinicians may face when treating patients. This review highlights four patients from the authors' everyday clinical work and offers guidance and practical considerations by neurologists with expertise in managing these complex conditions related to drug interactions, dosing, and side effects associated with fenfluramine. This is a graphical representation of the abstract and article highlights. image
引用
收藏
页码:1643 / 1657
页数:15
相关论文
共 50 条
  • [1] Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
    Balagura, Ganna
    Cacciatore, Marta
    Grasso, Eleonora A.
    Striano, Pasquale
    Verrotti, Alberto
    CNS DRUGS, 2020, 34 (10) : 1001 - 1007
  • [2] Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome
    Ganna Balagura
    Marta Cacciatore
    Eleonora A. Grasso
    Pasquale Striano
    Alberto Verrotti
    CNS Drugs, 2020, 34 : 1001 - 1007
  • [3] Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome
    Lattanzi, Simona
    Zaccara, Gaetano
    Russo, Emilio
    La Neve, Angela
    Lodi, Monica Anna Maria
    Striano, Pasquale
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (01) : 99 - 110
  • [4] Fenfluramine in clinical practice: new therapy option for Dravet and Lennox-Gastaut syndromes
    Muhle, Hiltrud
    Kurlemann, Gerhard
    Lehmann, Irene
    Hamer, Hajo
    Mayer, Thomas
    Potschka, Heidrun
    Schubert-Bast, Susanne
    Strzelczyk, Adam
    Pringsheim, Milka
    CLINICAL EPILEPTOLOGY, 2024, 37 (01) : 68 - 78
  • [5] Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
    Frampton, James E.
    DRUGS, 2023, 83 (10) : 923 - 934
  • [6] USE OF ADJUNCTIVE RUFINAMIDE FOR PATIENTS WITH LENNOX-GASTAUT SYNDROME IN CLINICAL PRACTICE
    Auvin, S.
    Papon, A.
    Bellavoine, V
    Storme, T.
    Merdariu, D.
    Ilea, A.
    Bourdon, O.
    Corny, J.
    EPILEPSIA, 2014, 55 : 111 - 111
  • [7] Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
    James E. Frampton
    Drugs, 2023, 83 : 923 - 934
  • [8] Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review
    Nordli, Douglas R.
    Galan, Fernando N.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2022, 24 (12) : 631 - 640
  • [9] Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain
    Garcia-Penas, Juan J.
    Nagel-Rein, Antonio Gil
    Sanchez-Carpintero, Rocio
    Villanueva-Haba, Vicente
    REVISTA DE NEUROLOGIA, 2021, 73 : S1 - S8
  • [10] Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review
    Douglas R. Nordli
    Fernando N. Galan
    Current Treatment Options in Neurology, 2022, 24 : 631 - 640